# ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers

> **NCT01875926** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 44 (actual)

## Conditions studied

- Healthy
- RSV Infection

## Interventions

- **BIOLOGICAL:** ALX-0171
- **BIOLOGICAL:** ALX-0171
- **BIOLOGICAL:** ALX-0171

## Key facts

- **NCT ID:** NCT01875926
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875926, "ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01875926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*